Product

Portfolio Intelligence Portside Congress trades Super-investors Economic calendar Earnings calendar Pricing

Company

About FAQs Contact Create account

Legal

Privacy Terms Portside rules

LIMN

Liminatus Pharma, Inc.

COMMON STOCK · NASDAQ

Price and daily changeSign in

Earnings12 Nov 2026

52-week rangeSign inDay rangeSign in

Loading evidence for LIMN

Market cap

Volume

Beta

Shares float

Short interest

0.14%

P/E (fwd)

PEG (fwd)

Rev growth (fwd)

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Create free account

Overview Statistics Statements Dividends🔒Momentum🔒Quant🔒Fair Value🔒Earnings Analysts🔒Insiders Smart Money Options🔒Insights🔒

Trading information

Beta: Sign in
Shares outstandingAs of 2026-08-14 · filed common shares: 67.16M
Shares float: Sign in
Float %: Sign in
Insider ownership: —
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 0.14%
Short ratioDays to cover, as published by FINRA: 1.34
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 50.30%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 45.10%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Avg volume (3 months)

Profitability

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equity: —
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -471.47%

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): —
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): -1342.21%
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-0.48

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $3.01M
Total cash: Sign in
Total debt: —
Debt / equity: —
Current ratioas of Jun 26: 1.12
Quick ratio: —
Operating cash flowTTM to Jun 26: -$3.97M
Free cash flow (quarter)Quarter: 2025-10-01 to 2025-12-31 · Not annualized: -$386.84K
TTM revenue / diluted share: —

LIMN stock Statistics — Liminatus Pharma, Inc. filings, insiders & smart money · Instaport